Home Drug Study Piperacillin/Tazobactam Drug Study

Piperacillin/Tazobactam Drug Study

Generic Name: Piperacillin/Tazobactam
Brand Name:Zosyn
Classifications:  antiinfective; beta-lactam antibiotic; antipseudomonal penicillin
Pregnancy Category: B
Availability  2 g, 3 g, 4 g injection


Antibacterial combination product consisting of the semisynthetic piperacillin and the beta-lactamase inhibitor tazobactam. Tazobactam component does not decrease the activity of the piperacillin component against susceptible organisms.

Therapeutic Effects  
Tazobactam is an inhibitor of a wide variety of bacterial beta–lactamases. It has little antibacterial activity itself; however, in combination with piperacillin, it extends the spectrum of bacteria that are susceptible to piperacillin. Two-drug combination has antibiotic activity against an extremely broad spectrum of gram-positive, gram-negative and anaerobic bacteria.

Treatment of moderate to severe appendicitis, uncomplicated and complicated skin and skin structure infections, endometritis, pelvic inflammatory disease, or nosocomial or community-acquired pneumonia caused by piperacillin-resistant, piperacillin/tazobactam-susceptible, beta-lactamase-producing bacteria.

Hypersensitivity to piperacillin, tazobactam, penicillins, cephalosporins, or beta-lactamase inhibitors such as clavulanic acid and sulbactam.

Cautious use
Kidney failure; pregnancy (category B), lactation. Safety and efficacy in children <12 y are not established.

Route & Dosage
adult:IV  3.375 g q6h, infused over 30 min, for 7–10 d
child:IV  <6 mo, 150–300 mg piperacillin/kg/d divided q6–8h; >=6 mo, 240 mg piperacillin component/kg/d divided q8h

Renal Impairment
Clcr 20–40 mL/min: 2.25 g q6h; <20 mL/min: 2.25 g q8h



  • For hemodialysis patients, the maximum dose is 2.25 g q8h; give one extra 0.75g dose after each dialysis period.

PREPARE intermittent: Reconstitute powder with 5 mL of diluent (e.g., D5W, NS); shake well until dissolved. Further dilute to at least 50 mL of selected diluent. Use single-dose vials immediately after reconstitution.

ADMINISTER intermittent: Give over at least 30 min.

Adverse effects
CNS:Headache, insomnia, fever.
GI:Diarrhea, constipation, nausea, vomiting, dyspepsia, pseudomembranous colitis.
Skin:Rash, pruritus, hypersensitivity reactions.

Nursing Implications  

Assessment & Drug Effects

  • Obtain history of hypersensitivity to penicillins, cephalosporins, or other drugs prior to administration.
  • Lab tests: C&S prior to first dose of the drug; start drug pending results. Monitor hematologic status with prolonged therapy (Hct and Hgb, CBC with differential and platelet count).
  • Monitor patient carefully during the first 30 min after initiation of the infusion for signs of hypersensitivity.

Patient & Family Education

  • Report rash, itching, or other signs of hypersensitivity immediately.
  • Report loose stools or diarrhea as these may indicate pseudomembranous colitis.
  • Do not breast feed while taking this drug without consulting physician.
This community comprises professional nurses who possess exceptional literary skills. They come together to share their expertise in theoretical and clinical knowledge, nursing tips, facts, statistics, healthcare information, news, disease data, care plans, drugs, and all aspects encompassed by the field of nursing. The information presented here is provided by individual authors and is expressed with courtesy. It is important to note that the views expressed on various topics may not necessarily represent those of the entire community. The articles submitted to this platform are original, meticulously checked for minor typographical errors, and formatted to ensure compatibility with the site. The site's primary goal is to consistently enhance and disseminate healthcare information that is pertinent to the ever-evolving world we live in today.


Please enter your comment!
Please enter your name here